Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Polymorphisms that are associated with drug-induced liver injury from statins

The most recent issue of Gastroenterology examines the association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study.

News image

Dr Ann Daly and colleagues from the United Kingdom performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury from licensed drugs without previously reported genetic risk factors.

The research team performed a GWAS of 862 persons with drug-induced liver injury, and 10,588 population-matched controls. 

The first set of cases was recruited before 2009 in Europe, and the United States. 

The second set of cases were identified from 2009 through 2013 from international collaborative studies performed in Europe, the United States, and South America. 

For the GWAS, the research team included only cases with patients of European ancestry associated with a particular drug. 

The polymorphism on chromosome 2 was associated with cholestatic and mixed drug-induced liver injury
Gastroenterology
The researchers used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. 

After the discovery analysis was concluded, the team validated their findings using data from 283 European patients with diagnosis of drug-induced liver injury associated with various drugs.

The team associated drug-induced liver injury with rs114577328, and with rs72631567 on chromosome 2. 

The researchers found that the association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related drug-induced liver injury. 

The variant on chromosome 2 was associated with drug-induced liver injury from a variety of drugs. 

Further phenotypic analysis indicated that the association between drug-induced liver injury, and A*33:01 was significant genome wide for cholestatic and mixed drug-induced liver injury, but not for hepatocellular drug-induced liver injury.

The team noted that the polymorphism on chromosome 2 was associated with cholestatic and mixed drug-induced liver injury as well as hepatocellular drug-induced liver injury. 

The researchers identified an association between rs28521457, and only hepatocellular drug-induced liver injury. 

The team did not associate any specific drug classes with genetic polymorphisms, except for statin-associated drug-induced liver injury, which was associated with rs116561224 on chromosome 18. 

The researchers validated the association between A*33:01 terbinafine- and sertraline-induced drug-induced liver injury. 

The team could not validate the association between drug-induced liver injury and rs72631567, rs28521457, or rs116561224.

Dr Daly's team concludes, "In a GWAS of persons of European descent with drug-induced liver injury, we associated HLA-A*33:01 with drug-induced liver injury due to terbinafine and possibly fenofibrate and ticlopidine."

"We identified polymorphisms that appear to be associated with drug-induced liver injury from statins, as well as 2 non-drug-specific risk factors."

Gastroenterol 2017: 152(5): 1078–1089 
10 April 2017

Go to top of page Email this page Email this page to a colleague

 20 October 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Hospital readmissions reduction program
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites
 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates
 22 September 2017 
MRI for liver metastatic colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us